Clinical Trials
Phase II Trial of SUL-238 Begins Dosing Patients
GEN Pharmaceuticals announced June 8, 2026 that the first patient has been dosed in a Phase II proof-of-concept trial for SUL-238, a novel compound targeting mitochondrial function in Parkinson's disease patients. The SHEPHERD study will assess how SUL-238 affects mitochondrial biology — the energy-producing structures inside cells that appear to malfunction in Parkinson's. This represents a fundamentally different approach than dopamine-based therapies, addressing what may be a root cause of neuronal death rather than just managing symptoms. *
markets.financialcontent.comBIIB122 LUMA Study Enters Phase 2b
Biogen and Denali Therapeutics are advancing the LUMA study, a Phase 2b multicenter trial evaluating BIIB122 — an LRRK2 inhibitor — in 648 patients with early-stage Parkinson's disease. Participants, aged 30-80 diagnosed within 2 years, receive either BIIB122 or placebo for 48 to 144 weeks. The primary goal: measuring whether the drug slows symptom worsening on the combined MDS-UPDRS Parts II and III scale. LRRK2 mutations account for roughly 5-10% of Parkinson's cases, but researchers believe the pathway may be relevant more broadly. Results are anticipated by late 2026. *
neurologylive.comUCSF Testing Blood Flow Restriction Therapy for DBS Patients
Researchers at UCSF are recruiting 10 idiopathic Parkinson's patients scheduled for deep brain stimulation (DBS) implantation to test whether blood flow restriction (BFR) training before surgery can improve outcomes. BFR involves wearing cuffs on limbs to partially restrict arterial flow while exercising with lighter loads — a technique shown to build strength more efficiently. The study will evaluate whether prehabilitation reduces surgical complications or accelerates post-operative recovery. This represents a growing trend toward prehabilitation protocols in movement disorder surgery. *
clinicaltrials.ucsf.edu
Breakthrough Treatments
Japan Approves World's First Stem Cell Therapy for Parkinson's
In a landmark decision March 2026, Japan's regulatory authorities approved the first stem cell-based therapy for Parkinson's disease — developed jointly by Sumitomo Pharma and Dr. Jun Takahashi at Kyoto University. The treatment involves transplanting induced pluripotent stem cells (iPSCs) into the brain to replace lost dopamine-producing neurons. Dr. Takahashi presented results at an American Parkinson Disease Association webinar showing promising signals in early trial participants. This marks a new era beyond symptom management toward actual cellular replacement and restoration. Western regulatory review is ongoing. *
apdaparkinson.orgFIU Compound Targets Cell Division Protein to Slow Parkinson's
Scientists at Florida International University have developed a novel compound targeting a protein that controls how cells divide and function. Early research suggests the compound could slow Parkinson's progression while simultaneously protecting against acute lung injury — a dangerous complication that affects some PD patients. The discovery addresses a fundamental cellular mechanism rather than dopamine replacement, potentially offering disease-modifying benefits. Preclinical data published March 2026 shows promise, with IND-enabling studies next. *
news.fiu.eduEmerging Pipeline: Five Compounds to Watch
Stanford Medicine's emerging treatments review highlights five compounds in active development: ambroxol (a GCase chaperone that helps clear toxic proteins), multiple NLRP3 inflammasome inhibitors (targeting neuroinflammation), AAV2-GDNF gene therapy (delivering neurotrophic factor directly), Solangepras/CVN-424 (a GPR6 inverse agonist targeting motor function), and Glovadoban (a D1 receptor modulator). Each addresses different mechanisms beyond dopamine replacement — representing a shift toward precision neuroprotection strategies. *
med.stanford.edu
Lifestyle Interventions
Parkinson Foundation and ACSM Publish Updated Exercise Recommendations
The Parkinson's Foundation and American College of Sports Medicine released revised exercise guidelines in February 2026, emphasizing that physical activity should be prescribed as early as possible following diagnosis — alongside medication, not after it. Key updates include specific recommendations for balance training, aerobic exercise, and strength work, with guidance tailored to disease stage. The guidelines stress that exercise appears safe even for prodromal individuals (those with REM sleep behavior disorder or genetic risk factors), potentially delaying onset or progression. The document represents the most authoritative clinical guidance on exercise prescription in Parkinson's. *
parkinson.orgNetwork Meta-Analysis Compares Exercise Types for Sleep Quality
A systematic review and network meta-analysis published in Frontiers in Physiology (2026) evaluated which exercise modalities most effectively improve sleep quality in Parkinson's disease patients — a common and burdensome non-motor symptom. The analysis compared aerobic exercise, resistance training, mind-body practices (tai chi, yoga), and dance-based interventions across multiple randomized controlled trials. Results are expected to guide clinicians toward evidence-based exercise prescriptions for sleep dysfunction, which affects up to 60% of PD patients and significantly impacts quality of life. *
frontiersin.orgCombined Lifestyle Approach Tested in SENSS Randomized Trial
A new randomized controlled trial called SENSS (Stress, Exercise, Nutrition, Sleep, Self-management) is evaluating whether an integrated, personalized, stepped-care lifestyle intervention produces better outcomes than single-modality approaches for people with Parkinson's. The study recognizes that patients face interconnected challenges — motor symptoms, mood, fatigue, sleep, and nutrition — that are rarely addressed in isolation. Results will inform whether bundled lifestyle prescriptions should become standard of care alongside pharmacological treatment. *
frontiersin.org
Emerging Research
GPNMB Protein Discovery Reveals How Parkinson's Spreads in Brain
Researchers have identified GPNMB (glycoprotein non-metastatic melanoma protein B) as a key protein that helps Parkinson's spread through the brain. The team found that microglia — the brain's immune cells — produce elevated GPNMB in response to neuron damage and death. When this protein is blocked in animal models, the spread of Parkinson's pathology slows significantly. This discovery points to microglia as a central driver of disease progression and suggests GPNMB as a potential therapeutic target to halt advancement rather than just manage symptoms. *
sciencedaily.comAlpha-Synuclein Bibliometric Analysis Maps 2015-2024 Research Landscape
A comprehensive bibliometric analysis published in Frontiers in Neurology (2026) mapped the global research landscape for alpha-synuclein — the misfolding protein that accumulates into the Lewy bodies characteristic of Parkinson's. The analysis of 10 years of publications reveals evolving research priorities, key institutions, and emerging therapeutic hypotheses. Understanding these trends helps identify where the field is heading and which scientific directions are gaining traction versus losing momentum. *
frontiersin.org
This report is for informational purposes only. The content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.